Stage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort
Authors:
- Msc Igor Kuchin MdMMMsc Igor Kuchin Md
- Sibylle Puntscher MscSMSibylle Puntscher Msc
- DrPH Gaby Sroczynski MPHDMDrPH Gaby Sroczynski MPH
- Marjan Arvandi MscMMMarjan Arvandi Msc
- Ma Julia Santamaria Navarro BscMBMa Julia Santamaria Navarro Bsc
- Anette SchragASAnette Schrag
- Fabian LeysFLFabian Leys
- Bianca CaliòBCBianca Caliò
- Frank JaguschFJFrank Jagusch
Open Access
- 6 November 2026
- journal article
- research article
- Published by Wiley in Movement Disorders
Abstract
Background: Multiple system atrophy (MSA) is a rare neurodegenerative disorder that severely impairs health‐related quality of life (HRQoL). Disease progression is assessed using the Unified Multiple System Atrophy Rating Scale Part IV (UMSARS IV), which defines five stages. However, stage‐specific HRQoL estimates, particularly health‐utility values, are unavailable. These estimates are essential for health‐economic evaluation of treatments and for supporting HRQoL as a clinical trial endpoint. Bayesian methods offer a practical approach for analyzing HRQoL in rare diseases. Objective: To estimate EQ‐5D‐based health‐utility values across UMSARS IV stages in MSA. Methods: EQ‐5D data from the European MSA Study Group cohort were analyzed. EQ‐5D‐3L responses were mapped to EQ‐5D‐5L health‐utility values using the German value set, where a value of 1 represents perfect health and lower or negative values indicate worse health. Bayesian modeling estimated stage‐specific health‐utility values, reporting posterior means and 95% credible intervals (CrI). Sensitivity analyses included alternative model specifications and imputations of missing UMSARS IV stages. Results: Stage‐specific EQ‐5D‐5L health‐utility values were 0.672 (95% CrI 0.628–0.719) for UMSARS IV Stage 1, 0.606 (95% CrI 0.523–0.679) for Stage 2, 0.517 (95% CrI 0.416–0.615) for Stage 3, 0.262 (95% CrI 0.158–0.364) for Stage 4, and 0.084 (95% CrI −0.045 to 0.217) for Stage 5. Bayesian models demonstrated good fit, capturing variability within stages and across countries. Sensitivity analyses confirmed robustness, with health‐utility values reflecting expected MSA progression. Conclusions: This study is the first to provide stage‐specific health‐utility values across all UMSARS IV stages, enabling health‐economic evaluations of emerging interventions and supporting HRQoL as a clinical trial endpoint. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords
Funding Information
- Austrian Science Fund (10.55776/FG27)
This publication has 65 references indexed in Scilit:
- Pain in Multiple System Atrophy: A Community‐Based SurveyMovement Disorders, 2024
- Health‐related quality of life in patients with multiple system atrophy using the EQ‐5D‐5LBrain and Behavior, 2022
- The Unified Multiple System Atrophy Rating Scale: Status, Critique, and RecommendationsMovement Disorders, 2022
- Disease Progression in Multiple System Atrophy—Novel Modeling Framework and Predictive FactorsMovement Disorders, 2022
- Power and sample size for multistate model analysis of longitudinal discrete outcomes in disease prevention trialsStatistics in Medicine, 2021
- Valuing health-related quality of life: An EQ-5D-5L value set for EnglandHealth Economics, 2017
- Assessment of quality of life with the multiple system atrophy health‐related quality of life scaleMovement Disorders, 2012
- Measuring health‐related quality of life in MSA: The MSA‐QoLMovement Disorders, 2007
- Health‐related quality of life in multiple system atrophyMovement Disorders, 2006
- Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)Movement Disorders, 2004